US EditionRize Oncology Inc. Announces Intention to Seek Shareholder Approval for Voluntary Delisting from the Canadian Securities Exchange
Summary by thenewswire.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Rize Oncology Inc. Announces Intention to Seek Shareholder Approval for Voluntary Delisting from the Canadian Securities Exchange
Kelowna, British Columbia – April 22, 2025 – TheNewswire - Rize Oncology Inc. (CSE: RIZE) (“Rize” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced that its Board of Directors has authorized the Company to seek shareholder approval for the voluntary delisting of its common shares from the Canadian Securities Exchange (“CSE”). The proposed delisting is subject to t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
